Next month, hundreds of thousands of spectators will gather at the Indianapolis Motor Speedway to watch the most technologically advanced cars in the world race past each other at speeds of over 200mph. Each racing machine is a testament to how far technology has advanced, with speed and safety continuously reaching new heights.
Eight miles from the track, a new 70 000 square-foot manufacturing plant nestled next to Indianapolis International Airport represents a different kind of technological innovation. The state-of-the-art facility is solely focused on producing radioligand therapies (RLTs), precision medicines designed to find and treat cancer.
Just like the engineers stretching the limits of racing technology, our team of dedicated Novartis associates is pushing the boundaries with the goal of changing the future of cancer treatment.
Novartis has spent years evolving our processes to ensure RLT doses can reach patients in a timely manner, and we are the only pharmaceutical company manufacturing and delivering these treatments commercially around the world. Since 2018, more than 10 000 cancer patients have been treated with Novartis RLTs.
The newest Novartis RLT manufacturing facility, sitting at the crossroads of America, is testament to our ambition to make radioligand therapy the next pillar in cancer care.
“People living with advanced cancers need as many options as they can get. Innovation is vital for patients, and facilities that help ensure the present and future delivery of treatment are critical for patients,” says Courtney Bugler. As President and CEO of ZERO Prostate Cancer, she knows better than most the need for facilities like the one in Indianapolis, and the treatments they produce.
